Item 2.02. Results of Operations and Financial Condition.
On
Item 7.01. Regulation FD Disclosure.
The information furnished on Exhibit 99.1 is incorporated by reference under this Item 7.01 as if fully set forth herein.
On
The information in this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits Exhibit No. Description Press release datedJanuary 9, 2023 entitled "BioCryst 99.1 Announces Preliminary Full Year 2022 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance" Press release datedJanuary 9, 2023 entitled "BioCryst Reports 99.2 Initial Clinical Data with Oral Factor D Inhibitor BCX10013Supporting Development as a Once-daily Treatment for Complement-mediated Diseases" 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
© Edgar Online, source